Senesco Adds Second Clinical Site to Evaluate SNS01-T in Multiple Myeloma
BRIDGEWATER, N.J.--(BUSINESS WIRE)--
Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) today announced that it has received Institutional Review Board approval and has finalized a clinical trial research agreement with the University of Arkansas for Medical Sciences (“UAMS”) in Little Rock, Arkansas to evaluate SNS01-T, the Company’s lead therapeutic candidate for the treatment of multiple myeloma in the on-going Phase 1b/2a study.
The University of Arkansas for Medical Sciences (“UAMS”) is one of the region's major academic health centers, located in Little Rock, Arkansas, with outreach programs operating in every county and a regional campus in Northwest Arkansas. The principal investigator in the study at UAMS is Saad Usmani, M.D., Director of Developmental Therapeutics in the Myeloma Institute for Research & Therapy.
“We are very pleased to have added UAMS as a clinical site along with the Mayo Clinic in order to accelerate patient enrollment and increase awareness of the SNS01-T study,” stated Leslie J. Browne, Ph.D, President and Chief Executive Officer of Senesco. “We believe that the addition of UAMS will help accomplish both of these objectives by broadening access to the trial.”
In the study, patients are dosed twice-weekly for 6 weeks followed by an observation period. The first group of three patients will receive 0.0125 mg/kg by intravenous infusion. At the end of their 6 weeks of dosing, safety data for the group will be reviewed before the subsequent group receives a higher dosage. The escalated doses administered to the second to fourth groups will be 0.05, 0.2 and 0.375 mg/kg, respectively. The study is an open-label, multiple-dose, dose-escalation study, which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to a total of approximately 15 relapsed or refractory multiple myeloma patients. While the primary objective of this study is to evaluate safety and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression will be assessed using multiple well-established metrics including measurement of the monoclonal protein (M-protein). Patient dosing in the study was initiated in November, 2011 at the Mayo Clinic in Rochester, Minnesota.
"The principal investigator in the study at UAMS is Saad Usmani, M.D., Director of Developmental Therapeutics in the Myeloma Institute for Research & Therapy."
Ahem....he also happens to be member of Celgene's consultancy advisory panel...
and working on other trials in collaboration with Celgene already:
He is top of his field...
See disclosures at bottom for the other big pharma consultancy panels he's on:
Onyx: Consultancy, Honoraria
Millinneum: Consultancy, Honoraria
Celgene: Consultancy, Honoraria, Speakers Bureau
SNS01-T is certainly on all big pharma involved in this space radar screens now...matter of showing first signs of efficacy and safety in patients and this thing will be sold foor an astronomical #
The stock price does not reflect it yet, but things are getting very very interesting at SNT.
Don't forget this news from January that I posted.
Bonky, you have a great find today, that adds yet another piece to the puzzle. The data from the phase I will be highly anticipated by Celgene.
Ultimately, I think they will buy Senesco if this works. The only question will be at what stage of the game. Some companies are being aquired at astronomical prices already just after phase 2 data.
We will have to wait and see if phase 1 data might be enough to entice them to try and steal SNT for a cheaper pricetag.....
Bonky, well done on uncovering the additional work by Dr. Usami. Celgene could be the white knight for SNT. Hopefully, the SNT board will protect the long term shareholders if there is a buyout or merger.
Right on all accounts Bonky--the indication of a second sight is quite positive and will accelerate the trials.
The connection to Celegene is wonderful.
The need to show efficacy is paramount.
We take another step forward....best to all!!